Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ALT 110; Brain cancer vaccine - Celldex Therapeutics; CDX-110; PF-04948568; PF-04948569; PF-4948568; PF-4948569; Rindo; Rintega; SPX 110

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University; Johns Hopkins University
  • Developer Celldex Therapeutics Inc
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma; Solid tumours

Most Recent Events

  • 16 Oct 2017 Expanded access no longer available for rindopepimut in Glioblastoma (Recurrent, Second-line therapy or greater) (NCT03068650)
  • 08 Aug 2016 Discontinued - Phase-I for Solid tumours in USA (Intradermal)
  • 08 Aug 2016 Discontinued - Phase-II for Glioblastoma (Combination therapy, Second-line therapy or greater) in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top